Use of Toll-Like Receptor 3 Agonists against Respiratory Viral Infections

PDF

Authors
  1. Christopher, M.E.
  2. Wong, J.P.
Corporate Authors
Defence R&D Canada - Suffield, Ralston ALTA (CAN)
Abstract
Respiratory RNA viruses are constantly evolving, thus requiring development of additional prophylactic and therapeutic strategies. Harnessing the innate immune system to non-specifically respond to viral infection has the advantage of being able to circumvent viral mutations that render the virus resistant to a particular therapeutic agent. Viruses are recognized by various cellular receptors, including Toll-like receptor (TLR) 3 which recognizes double-stranded (ds)RNA produced during the viral replication cycle. TLR3 agonists include synthetic dsRNA such as poly (IC), poly (ICLC) and poly (AU). These agents have been evaluated and found to be effective against a number of viral agents. One major limitation has been the toxicity associated with administration of these drugs. Significant time and effort have been spent to develop alternatives/modifications that will minimize these adverse effects. This review will focus on the TLR3 agonist, poly (IC)/(ICLC) with respect to its use in treatment/prevention of respiratory viral infections.
Report Number
DRDC-SUFFIELD-SL-2010-170 — Scientific Literature
Date of publication
01 Jan 2011
Number of Pages
12
Reprinted from
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, vol 10, 2011, p 327-338
DSTKIM No
CA036395
CANDIS No
535995
Format(s):
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: